(PASG) Passage Bio, Inc. PESTLE Analysis Research

Passage Bio, Inc.'s pipeline is tightly tied to rare-disease policy: GM1 gangliosidosis, FTD-GRN, and Krabbe disease all fall into orphan-drug space, where the U.S. gives 7 years of market exclusivity and the EU gives 10 years. For very small populations like Krabbe disease, often cited at about 1 in 100,000 births, public support can make or break development economics.

• Orphan rules speed trials and approvals
• Exclusivity protects pricing power
• Policy support underpins value

Passage Bio, Inc. relies on Catalent Maryland, Inc. for development services and clinical supply, so U.S. facility policy and interstate transport rules can directly affect trial timing. Any tighter FDA oversight, lab capacity limits, or freight delays can slow batch release and patient dosing. In 2024, Catalent was sold to Novo Holdings, which makes vendor stability and contract continuity even more important for Passage Bio, Inc.

• One U.S. supplier concentration risk
• FDA and logistics delays can slow trials
• Policy shifts can hit supply timing

Passage Bio, Inc. uses partnership-based cost sharing with the University of Pennsylvania and Catalent to split development work and avoid building every skill in-house. That can keep near-term fixed costs lower while still preserving access to gene-therapy know-how and manufacturing support. For a pre-revenue biotech, that matters because cash burn falls when outside partners absorb part of the load.

• Shares development spend
• Avoids duplicate build-out
• Keeps technical access
• Supports lower fixed costs

Passage Bio, Inc. can price rare-disease therapies at a premium because each target is severe and often affects only a few thousand patients. Benchmarks are high: Hemgenix launched at $3.5 million and Lenmeldy at $4.25 million, but payers still require strong proof of benefit before covering that spend. So revenue depends on whether clinical data are strong enough to win reimbursement and avoid access limits.

• Rare disease supports premium pricing.
• Payer coverage is the real gate.
• Proof of benefit drives access.

Passage Bio, Inc. targets rare diseases that often start in childhood, and about 70% of rare diseases begin before age 18, so parents and caregivers usually shape treatment choices. With an estimated 300 million people living with rare diseases worldwide, social acceptance of experimental gene therapy can affect trial consent, follow-up, and trust.

• Families often make the final call.
• Clear consent lifts trial participation.
• High hopes raise communication risk.

That makes plain updates vital: if expectations are not set early, missed visits and dropouts can rise, which can slow data collection and weaken study quality.

Awareness of gene therapy has risen across rare-disease communities, helping Passage Bio, Inc. reach better-informed patients and clinicians. More doctors now understand vector-based delivery, and that can lift referrals, trial enrollment, and education around its programs. Rare diseases still affect more than 300 million people worldwide, so even small gains in awareness can matter.

• Higher gene therapy awareness supports referrals.
• Clinicians better understand vector-based approaches.
• Rare-disease outreach can boost trial interest.

Passage Bio targets the brain, where delivery is still the hardest gene-therapy step. The blood-brain barrier blocks more than 98% of large molecules, so vector spread, capsid choice, and dose control can make or break exposure in the CNS.

CSF volume is about 150 mL, so even small dosing shifts can change tissue coverage and safety. That makes biodistribution data, peripheral spillover, and repeatability key technical risks for Passage Bio.

• BBB blocks >98% of large molecules
• CSF volume is ~150 mL
• Vector spread drives CNS exposure
• Dose control affects safety

Passage Bio, Inc. relies on Catalent Maryland, Inc. for clinical supply, so its gene therapy work depends on a third party for vector production, fill-finish, and release testing. That setup raises execution risk: if batch consistency slips, trial dosing can stall and timelines can move fast. For a small-cap biotech with about $12.4 million in cash and equivalents at 2025 year-end, any manufacturing delay can hit runway and program continuity.

• External CDMO dependency
• Batch consistency is critical
• Delays can disrupt trials
• Runway is tight

Passage Bio relies on two key legal contracts: a research collaboration with the University of Pennsylvania and a development services agreement with Catalent Maryland. These deals control IP rights, manufacturing duties, and confidentiality, so any dispute or amendment can delay programs that still lack approved products. For a company with only a handful of active gene-therapy assets, even one contract change can move timelines.

• University of Pennsylvania: IP and research terms
• Catalent Maryland: GMP manufacturing duties
• Contract changes can delay clinical timelines
• Confidentiality protects proprietary know-how

Passage Bio, Inc. depends on patent cover for its proprietary capsids and gene constructs, because U.S. utility patents usually last 20 years from filing, and platform know-how can be harder to copy than a single asset. In a multi-program model, legal defense matters more, since one weak claim can spill into several programs and cut future licensing value. Strong IP also helps justify partnering deals, where buyers pay for freedom to operate, not just data.

• Patent cover protects capsids and constructs.
• Know-how control raises copy risk barriers.
• Defensible IP supports partnering value.

Passage Bio, Inc. relies partly on Catalent Maryland, Inc. for clinical supply, so a slice of its environmental footprint sits outside its own plants. That makes waste handling, air permits, and emissions controls at partner sites part of Passage Bio, Inc.’s ESG profile.

For a small-cap biotech, third-party manufacturing risk matters because one vendor issue can disrupt supply and add cost fast; external CDMOs often manage solvent waste, energy use, and biologic waste streams that shape reported Scope 3 impact.

• Shared footprint with Catalent Maryland, Inc.
• Partner waste and emissions affect ESG score
• Supply risk and compliance sit off-site

For Passage Bio, Inc., a one-time rare-disease therapy can cut long treatment cycles, fewer clinic visits, infusions, and repeat drug use, which can reduce healthcare resource use over time. That creates an environmental edge versus lifelong therapies, but only if the benefit lasts and patients adopt it in real practice. The case is stronger in diseases where chronic care can run for decades.

• Less repeat dosing can lower resource use.
• Durability drives the environmental gain.
• Real-world uptake decides the impact.